Mark Zuckerberg, CEO of Meta, has hired three researchers from OpenAI to bolster his company’s work on artificial intelligence. This strategic move aims to guide Meta Platforms through its current AI challenges. The social-media corporation brought aboard Lucas Beyer, Alexander Kolesnikov, and Xiaohua Zhai, all of whom previously held positions at OpenAI’s branch in Zurich, as per sources privy to this information. These individuals established OpenAI’s location in Zurich towards the end of last year. Prior to their time at OpenAI, they collaborated closely within Google DeepMind, which is the organization’s artificial intelligence division. A representative from OpenAI verified that the three scientists have departed from the organization. Zuckerberg has been on an intense recruiting drive To correct the company’s AI initiatives following the underwhelming reception of its most recent model, he has sometimes proposed giving researchers up to $100 million to become part o...
The shares of Hims took a sharp dive on Monday following Novo Nordisk NVO concluded its one-month partnership with the telehealth provider due to worries regarding the firm’s sale of less expensive imitations of the weight-loss medication Wegovy.
The drugmaker accused Hims & Hers Health HIMS was accused by Novo Nordisk of engaging in "misleading marketing and sales practices involving counterfeit copies of Wegovy that compromise patient safety." As a result, Novo decided not to permit Wegovy to be included with a Hims subscription for $599 per month anymore. This agreement was made back in April, leading to a significant surge in Hims' stock price.
Kindly view the video available at Investors.com titled "The Booming Weight-Loss Drug Industry: Which Healthcare Company Will Claim Top Spot?"
During early trading sessions of today’s stock market, shares of Hims plummeted over 23%, reaching $48.78. The stocks claimed the third position in terms of trade volume. IBD 50 Here’s a list of top emerging growth stocks. This week, Hims stock has been included as highlighted by Investor's Business Daily. New America stock.
Even after partnering with Novo, Hims & Hers continues to offer their own compounded form of semaglutide, which is the active component in Wegovy. These compounding pharmacies have been producing replicas of brand-name medications to address shortages. However, earlier this year, the FDA determined that semaglutide is now readily available and not in short supply anymore.
Representatives from Novo Nordisk and Hims & Hers did not promptly respond to requests for comment.
More to follow.
Follow Allison Gatlin on Twitter/X at @AGatlin_IBD .
YOU MAY ALSO LIKE:
The Ongoing FDA Overhaul May Affect Genetic Therapies
The Upcoming Review of Amgen's Obesity Treatment Awaits. Here’s What Investors Have Their Eyes On.
Daily IBD Stock Pick: Learn How to Identify, Monitor and Purchase Top-performing Shares
Choices Trading: Beginning With Options, Managing Risk
Check out the IBD stock lists and obtain pass/fail ratings for all your stocks using IBD Digital.